NurExone Biologic Inc. Announces Strategic Expansion to US Financial Markets with Approval of OTCQB Listing Application and DTC Eligibility
2024年4月25日 - 9:35PM
NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the
“
Company” or “
NurExone”), a
pioneering biopharmaceutical company is pleased to announce that
its common shares are now quoted for trading on the OTCQB® Venture
Market (the "
OTCQB") under the symbol NRXBF. The
OTCQB listing enhances visibility and facilitates trading by US
institutional and retail investors.
As the sole public company developing therapies
for spinal cord injury treatment with exosomes, NurExone is proud
to broaden its financial market access. The OTCQB, a renowned U.S.
trading platform, is a pivotal gateway to US trading, fostering an
environment conducive to informed investment decisions. This
enhances opportunities to attract investment and optimize
shareholder value.
The Company is delighted to announce that it has
also received Depository Trust Company ("DTC")
eligibility for its shares on the OTCQB. DTC eligibility expands
the Company's stock reach to a wider audience of potential
investors and brokerage firms that mandate additional compliance
measures. This move aims to enhance accessibility and potentially
boost liquidity through online transactions.
Mr. Yoram Drucker, chairman of NurExone’s board,
expressed his enthusiasm, stating, “Securing a place on the OTCQB
and obtaining DTC eligibility exemplify our dedication to enriching
shareholder engagement and liquidity. These achievements enable US
investors to easily access and invest in NurExone. As pioneers in
exosome-loaded nanodrug development for a variety of clinical
conditions, notably spinal cord injuries, we're excited to provide
the investing community with expanded avenues to join our
innovation.”
Dr. Lior Shaltiel, CEO of NurExone added
“Expanding our investor base will accelerate our efforts in
developing solutions and therapies for the hundreds of thousands of
patients worldwide suffering from traumatic spinal cord
injuries.”
NurExone Biologic's common shares will continue
trading on the TSX Venture Exchange (the “TSXV”)
and on several stock exchanges in Germany including Frankfurt,
Munich, or Tradegate. If, and when, the Company's common shares
start to trade on the OTCQB, the Company's common shares will
continue to trade on the TSXV under the symbol ‘NRX’ and in Germany
under the symbol ‘J90’.
About NurExone Biologic
Inc.
NurExone Biologic Inc. is a TSXV listed
pharmaceutical Company that is developing a platform for
biologically-guided exosome-based therapies to be delivered,
non-invasively, to patients who have suffered Central Nervous
System injuries. The Company’s first product, ExoPTEN for acute
spinal cord injury, was proven to recover motor function in 75% of
laboratory rats when administered intranasally. ExoPTEN has been
granted Orphan Drug Designation by the FDA. The NurExone platform
technology is expected to offer novel solutions to drug companies
interested in noninvasive targeted drug delivery for other
indications.
For additional information, please visit
www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook,
or YouTube.
For more information, please contact:
Dr. Lior ShaltielChief Executive Officer and DirectorPhone:
+972-52-4803034Email: info@nurexone.com
Thesis Capital Inc.Investment Relation - CanadaPhone: +1
905-347-5569Email: IR@nurexone.com
Dr. Eva ReuterInvestment Relation - GermanyPhone:
+49-69-1532-5857Email: e.reuter@dr-reuter.eu
FORWARD-LOOKING
STATEMENTS
This press release contains certain
forward-looking statements, including statements about the
Company's future plans and intellectual property, the scientific
and development and commercial activities to be carried out by the
company, the efficient loading of exosomes, future potential
manufacturing, clinical, licensing and marketing activities the
treatment of certain conditions, trading the Company’s common
shares on the OTCQB, and DTC eligibility. Wherever possible, words
such as "may", "will", "should", "could", "expect", "plan",
"intend", "anticipate", "believe", "estimate", "predict" or
"potential" or the negative or other variations of these words, or
similar words or phrases, have been used to identify these
forward-looking statements. These statements reflect management's
current beliefs and are based on information currently available to
management as at the date hereof. Forward-looking statements
involve significant risk, uncertainties and assumptions. Many
factors could cause actual results, performance or achievements to
differ materially from the results discussed or implied in the
forward-looking statements. Certain assumptions include the ability
of the Company to commercialize its intellectual property
internally and through licensing and that the Company has the
appropriate team in order to realize commercialization. Risks and
uncertainties include, but are not limited to, risks related to the
Company's early stage of development, lack of revenues to date,
government regulation, market acceptance for its products, rapid
technological change, dependence on key personnel, protection of
the Company's intellectual property and dependence on the Company's
strategic partners. These factors should be considered carefully
and readers should not place undue reliance on the forward-looking
statements. Although the forward-looking statements contained in
this press release are based upon what management believes to be
reasonable assumptions, the Company cannot assure readers that
actual results will be consistent with these forward-looking
statements. These forward-looking statements are made as of the
date of this press release, and the Company assumes no obligation
to update or revise them to reflect new events or circumstances,
except as required by law.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
NurExone Biologic (TG:J90)
過去 株価チャート
から 8 2024 まで 9 2024
NurExone Biologic (TG:J90)
過去 株価チャート
から 9 2023 まで 9 2024